The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma
Open accessAbstract
BACKGROUND: The primary objective of this study was to determine whether addition of the selective P‐glycoprotein (P‐gp) inhibitor tariquidar (XR9576) to chemotherapy could induce an objective tumor response in patients who previously were resistant to the same agents. The secondary objectives were to evaluate P‐gp expression by immunohistochemistry (IHC), to determine functional activity of the P‐gp transporter before and after administration of tariquidar with serial technetium‐99m (99m Tc)‐sestamibi scans, and to correlate those parameters with clinical response. METHODS: Seventeen women with Stage III–IV breast carcinoma were included in the study who progressed (n = 13 women) or had stable disease (n = 4 women) on doxorubicin‐containing or taxane‐containing chemotherapy regimens. During the study, the same chemotherapy was continued without dose modifications, but tariquidar (150 mg intravenously) was added to the treatment regimen. RESULTS: Thirty‐six percent of patients had P‐gp‐positive tumors by IHC, and 5 patients (29%) experienced increases ≥ 10% in sestamibi uptake (median increase, 40%; range, 10–63%) after the administration of tariquidar. There was one partial response in a patient who had the greatest increase in sestamibi uptake and who also showed inducible P‐gp expression. There was one patient who experienced severe doxorubicin/docetaxel‐related toxicity after tariquidar was added to her chemotherapy regimen. CONCLUSIONS: Tariquidar showed limited clinical activity to restore sensitivity to anthracycline or taxane chemotherapy. Functional imaging of the tumor with 99m Tc‐sestamibi scans before and after administration of multidrug‐resistance inhibitor may be useful to identify the small subset of patients who could benefit from multidrug‐resistance modulation in future trials. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Hyafil, F., Pauwels-Vergely, C., Vignaud, P. D., & Grand‐Perret, T. (1993) · PubMed · Cited by 525
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434
Boesch, D., Gavériaux‐Ruff, C., Jachez, B., Pourtier, A., Bollinger, P., & Loor, F. (1991) · PubMed · Cited by 360
(2001) · PubMed · Cited by 350
Clinical trials of agents that reverse multidrug resistance. A literature review
Raderer, M., & Scheithauer, W. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12<3553::aid-cncr2820721203>3.0.co;2-b · Cited by 228
Clinical trials of agents that reverse multidrug-resistance.
Gottesman, M. M., & Pastan, I. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.409 · Cited by 176
Ciarmiello, A., Vecchio, S. D., Silvestro, P., Potena, M. I., Carriero, M. V., Thomas, R., Botti, G., D’Aiuto, G., & Salvatore, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1677 · Cited by 149
Agrawal, M., Abraham, J., Balis, F. M., Edgerly, M., Stein, W. D., Bates, S. E., Fojo, T., & Chen, C. C. (2003) · PubMed · Cited by 135
Pharmacologic approaches to reversing multidrug resistance.
Sikic, B. I. (1997) · PubMed · Cited by 131
Stewart, A. J., Steiner, J., MELLOWS, G., Laguda, B., Norris, D., & Bevan, P. (2000) · PubMed · Cited by 122
Luker, G. D., Fracasso, P. M., Dobkin, J. B., & Piwnica-Worms, D. (1997) · PubMed · Cited by 120
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., & Giaccone, G. (1997) · International Journal of Cancer · Cited by 112
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen, C. C., Meadows, B., Regis, J. T., Kalafsky, G., Fojo, T., Carrasquillo, J. A., & Bates, S. E. (1997) · PubMed · Cited by 102
MRP and MDR1 gene expression in primary breast carcinomas.
Filipits, M., Suchomel, R. W., Dekan, G., Haider, K., Valdimarsson, G., Depisch, D., & Pirker, R. (1996) · PubMed · Cited by 94
Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C. A., Tkaczuk, K., Verma, S., Overmoyer, B. A., Garg, V., Ette, E., Harding, M. W., et al. (2002) · PubMed · Cited by 82
Bates, S. E., Bakke, S., Kang, M. H., Robey, R. W., Zhai, S., Thambi, P. M., Chen, C. C., Patil, S., Smith, T., Steinberg, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0829-03 · Cited by 71
Warner, E., Hedley, D. W., Andrulis, I. L., Myers, R. E., Trudeau, M. G., Warr, D. G., Pritchard, K. I., Blackstein, M. E., Goss, P. E., Franssen, E., et al. (1998) · PubMed · Cited by 48
Chung, H. C., Rha, S. Y., Kim, J. H., Roh, J. K., Min, J. S., Lee, K. S., Kim, B., & Lee, K. B. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005739525196 · Cited by 44
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
P-glycoprotein Inhibition for Optimal Drug Delivery
Amin, M. L. (2013) · Drug Target Insights · doi:10.4137/dti.s12519 · Cited by 624
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Metadata
- Authors
- Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., Rouzier, R., Boniface, G., & Hortobagyi, G. N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-06-28
- Volume
- 104
- Issue
- 4
- Pages
- 682-691
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2103394810
- Cited by
- 302
- References
- 21
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.